|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12345678910111213...1819» |
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment change, Trial termination, Trial primary completion date: AMVISION-1: Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Aug 11, 2015
P3, N=478, Terminated, Sponsor: Amgen
N=630 --> 478 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Sep 2015; Sponsor Decision
- ||| calcipotriol/betamethasone dipropionate / Generic mfg.
Trial completion, HEOR: An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex (clinicaltrials.gov) - Jul 22, 2015
P=N/A, N=147, Completed, Sponsor: LEO Pharma
N=630 --> 478 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Sep 2015; Sponsor Decision Active, not recruiting --> Completed
- Trial termination, Trial primary completion date: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=35, Terminated, Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine
Active, not recruiting --> Completed Suspended --> Terminated | Trial primary completion date: Dec 2015 --> Aug 2015; Paitents were unwilling to be randomly assigned to a placebo group.
- tacrolimus topical / Generic mfg.
Enrollment change, Trial termination: Tacrolimus Ointment in Oral Lichen Planus (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=28, Terminated, Sponsor: University of Oulu
Suspended --> Terminated | Trial primary completion date: Dec 2015 --> Aug 2015; Paitents were unwilling to be randomly assigned to a placebo group. N=40 --> 28 | Recruiting --> Terminated; Lack of resources
- Trial primary completion date: Premature Coronary Artery Disease (CAD) in Severe Psoriasis (clinicaltrials.gov) - Jul 15, 2015
P1, N=120, Active, not recruiting, Sponsor: University of Michigan
N=40 --> 28 | Recruiting --> Terminated; Lack of resources Trial primary completion date: Oct 2014 --> Oct 2015
- sonelokimab (M1095) / Avillion, MoonLake Immunotherap
Enrollment closed: Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects (clinicaltrials.gov) - Jul 15, 2015
P1, N=40, Active, not recruiting, Sponsor: Merck KGaA
Trial primary completion date: Oct 2014 --> Oct 2015 Recruiting --> Active, not recruiting
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Jul 14, 2015
P3, N=200, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Oct 2017
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Trial primary completion date: Use of Botulinum Toxin to Treat Psoriasis (clinicaltrials.gov) - Jul 14, 2015
P1, N=10, Active, not recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Mar 2016 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- ||| Cibinqo (abrocitinib) / Pfizer
Enrollment closed: Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis (clinicaltrials.gov) - Jul 13, 2015
P2, N=196, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Active, not recruiting
- || Enrollment closed, Trial primary completion date: To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Jul 13, 2015
P=N/A, N=125, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016
- || Enbrel (etanercept) / Pfizer, Amgen
Phase classification, Trial primary completion date: Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis (clinicaltrials.gov) - Jul 8, 2015
P=N/A, N=128, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: May 2015 --> Apr 2016 | Phase classification: P4 --> PN/A
- ||| namilumab (IZN-101) / Amgen, Izana Biosci
Clinical: Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis (clinicaltrials.gov) - Jul 2, 2015
P2, N=120, Recruiting, Sponsor: Takeda
Trial primary completion date: May 2015 --> Apr 2016 | Phase classification: P4 --> PN/A N=100 --> 120
- |||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Enrollment open: Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet (clinicaltrials.gov) - Jul 1, 2015
P3, N=200, Recruiting, Sponsor: LEO Pharma
N=100 --> 120 Not yet recruiting --> Recruiting
- Bimzelx (bimekizumab) / UCB
Clinical: Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Jul 1, 2015
P1, N=50, Active, not recruiting, Sponsor: UCB Celltech
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Trial completion: A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) (clinicaltrials.gov) - Jun 30, 2015
P4, N=1846, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Erelzi (etanercept-szzs) / Sandoz
Trial completion, Trial primary completion date: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (clinicaltrials.gov) - Jun 25, 2015
P3, N=531, Completed, Sponsor: Sandoz
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jun 2014
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jun 24, 2015
P3, N=400, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jun 2014 Recruiting --> Active, not recruiting
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jun 20, 2015
P3, N=400, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Jan 2016
- Vectical (calcitriol) / Nestle
Trial completion: Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis (clinicaltrials.gov) - Jun 18, 2015
P4, N=30, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Mar 2015 --> Jan 2016 Recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: VIP-Et: Vascular Inflammation in Psoriasis - Extension Study (clinicaltrials.gov) - Jun 12, 2015
P4, N=96, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Recruiting --> Active, not recruiting
- Humira (adalimumab) / AbbVie
Enrollment closed: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jun 12, 2015
P4, N=96, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- anti-TNF/IL-17A FynomAb (COVA322) / J&J
Trial primary completion date: Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=39, Recruiting, Sponsor: Covagen
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Nov 2015
- Trial primary completion date: Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=43, Recruiting, Sponsor: Rockefeller University
Trial primary completion date: Apr 2015 --> Nov 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- Trial primary completion date: MMAPPS: Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Jan 2015 --> Jan 2016
- bexarotene/betamethasone dipropionate (LAS 41004) / Almirall
Trial completion: Left/Right: A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis (clinicaltrials.gov) - Jun 10, 2015
P2a, N=40, Completed, Sponsor: Almirall, S.A.
Trial primary completion date: Jan 2015 --> Jan 2016 Recruiting --> Completed
- ||||| Skilarence (dimethyl fumarate) / Almirall
Enrollment closed: LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Jun 10, 2015
P3, N=690, Active, not recruiting, Sponsor: Almirall, S.A.
Recruiting --> Completed Recruiting --> Active, not recruiting
- tazarotene topical / Generic mfg.
Trial completion, Trial primary completion date: Efficacy and Safety of Tazarotene Gel in Nail Psoriasis (clinicaltrials.gov) - Jun 10, 2015
P2, N=66, Completed, Sponsor: Almirall, S.A.
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Nov 2014 --> May 2014
- Stelara (ustekinumab) / J&J
Trial completion, HEOR: The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment (clinicaltrials.gov) - Jun 1, 2015
P4, N=35, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> May 2014 Recruiting --> Completed
- ||||||| methotrexate / Generic mfg.
Trial completion: TICOPA: TIght COntrol of Psoriatic Arthritis (clinicaltrials.gov) - May 28, 2015
P3, N=206, Completed, Sponsor: Julia Brown
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions (clinicaltrials.gov) - May 22, 2015
P1/2, N=28, Terminated, Sponsor: University of Michigan
Recruiting --> Completed N=50 --> 28
- | Trial completion: A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - May 19, 2015
P2, N=10, Completed, Sponsor: University of Michigan
N=50 --> 28 No longer recruiting --> Completed
- | neihulizumab (ALTB-168) / AltruBio
Trial completion: A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - May 12, 2015
P2, N=50, Completed, Sponsor: AbGenomics B.V Taiwan Branch
No longer recruiting --> Completed Recruiting --> Completed
- |||| Sorilux (calcipotriene foam) / Mayne Pharma
Trial completion, Combination therapy: Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis (clinicaltrials.gov) - May 12, 2015
P4, N=60, Completed, Sponsor: Leon Kircik, M.D.
Recruiting --> Completed Active, not recruiting --> Completed
- trichuris suis ova (CNDO-201) / Fortress
Enrollment change, Trial withdrawal: TSO for Plaque Psoriasis (clinicaltrials.gov) - May 6, 2015
P2, N=0, Withdrawn, Sponsor: Coronado Biosciences, Inc.
Active, not recruiting --> Completed N=25 --> 0 | Not yet recruiting --> Withdrawn
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - May 6, 2015
P3, N=200, Active, not recruiting, Sponsor: AbbVie
N=25 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- ||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial initiation date: A Study of Golimumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - May 5, 2015
P3, N=440, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Initiation date: Sep 2014 --> Apr 2014
- || brepocitinib (PF-06700841) / Pfizer
PK/PD data: A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation (clinicaltrials.gov) - May 4, 2015
P1, N=158, Recruiting, Sponsor: Pfizer
Initiation date: Sep 2014 --> Apr 2014 N=104 --> 158
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - May 1, 2015
P=N/A, N=80, Recruiting, Sponsor: AbbVie
N=104 --> 158 N=140 --> 80
- Impoyz (clobetasol) / Encore
Trial primary completion date: DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Apr 30, 2015
P2, N=50, Recruiting, Sponsor: Promius Pharma, LLC
N=140 --> 80 Trial primary completion date: Jan 2015 --> Aug 2015
- Enrollment change, Trial primary completion date: Reduction of Pain Caused by Biologic Drugs in Psoriasis (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=200, Recruiting, Sponsor: Mount Sinai School of Medicine
Trial primary completion date: Jan 2015 --> Aug 2015 N=110 --> 200 | Trial primary completion date: Jan 2015 --> Dec 2015
- prednisone / Generic mfg.
Trial completion, HEOR: The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus (clinicaltrials.gov) - Apr 28, 2015
P2, N=30, Completed, Sponsor: October 6 University
N=110 --> 200 | Trial primary completion date: Jan 2015 --> Dec 2015 Enrolling by invitation --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Apr 22, 2015
P3, N=200, Recruiting, Sponsor: AbbVie
Enrolling by invitation --> Completed Trial primary completion date: Feb 2015 --> Feb 2016
- Enrollment change, Trial suspension: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=35, Suspended, Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine
Trial primary completion date: Feb 2015 --> Feb 2016 N=384 --> 35 | Recruiting --> Suspended
- Trial primary completion date: Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications (clinicaltrials.gov) - Apr 21, 2015
P2, N=5, Terminated, Sponsor: University of Tennessee
N=384 --> 35 | Recruiting --> Suspended Trial primary completion date: Dec 2010 --> Nov 2009
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=288, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2010 --> Nov 2009 N=203 --> 288
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change, Combination therapy: Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Apr 21, 2015
P4, N=0, Withdrawn, Sponsor: Stiefel, a GSK Company
N=203 --> 288 N=30 --> 0
- ||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab biosimilar) / Amgen, Daiichi Sankyo
Trial completion: Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Apr 20, 2015
P3, N=350, Completed, Sponsor: Amgen
N=30 --> 0 Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change, Trial primary completion date, Immunomodulating: Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab. (clinicaltrials.gov) - Apr 20, 2015
P=N/A, N=17, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=52 --> 17 | Trial primary completion date: Mar 2014 --> Mar 2015
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Apr 19, 2015
P4, N=106, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed | N=52 --> 17 | Trial primary completion date: Mar 2014 --> Mar 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- Sorilux (calcipotriene foam) / Mayne Pharma
Trial primary completion date: Safety, Tolerability, PD & PK of Calcipotriene 0.005% Foam, Under Maximal Use in 12-16 Year Olds With Plaque Psoriasis (clinicaltrials.gov) - Apr 19, 2015
P1, N=30, Recruiting, Sponsor: Stiefel, a GSK Company
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Jan 2015 --> Aug 2015